Risk Factors for and Clinical Outcomes of Polymicrobial Acinetobacter baumannii Bloodstream Infections
Table 4
Comparisons of the microbiological characteristics of monomicrobial AB-BSIs and polymicrobial AB-BSIs.
Antibiotic resistance
Total ()
Monomicrobial ()
Polymicrobial ()
value
Source of BSI
Respiratory tract
154 (25.9%)
135 (28.8%)
19 (15.1%)
0.002
Central venous catheter
89 (15%)
64 (13.7%)
25 (19.8%)
0.085
Skin and soft tissue
85 (14.3%)
49 (10.5%)
36 (28.6%)
<0.001
Intracranial
43 (7.2%)
40 (8.5%)
3 (2.4%)
0.018
Primary
133 (22.4%)
107 (22.9%)
26 (20.6%)
0.594
Othersa
90 (15.2%)
73 (15.6%)
17 (13.5%)
0.552
Antibiotic resistance of ABb
Amikacin (330 vs. 81)c
145 (24.4%)
115 (24.6%)
30 (23.8%)
0.380
Ciprofloxacin (467 vs. 126)c
545 (91.8%)
431 (92.1%)
114 (90.5%)
0.701
Ceftazidime (463 vs. 125)c
556 (93.6%)
440 (94%)
116 (92.1%)
0.598
Tobramycin (460 vs. 121)c
409 (68.9%)
316 (67.5%)
93 (73.8%)
0.068
Levofloxacin (467 vs. 126)c
519 (87.4%)
412 (88%)
107 (84.9%)
0.532
Nitrofurantoin (431 vs. 117)c
541 (91.1%)
425 (90.8%)
116 (92.1%)
0.864
Cefoperazone/sulbactam (460 vs. 125)c
520 (87.5%)
409 (87.4%)
111 (88.1%)
0.756
Gentamicin (455 vs. 121)c
461 (77.6%)
358 (76.5%)
103 (81.7%)
0.229
Piperacillin/tazobactam (241 vs. 61)c
273 (46%)
217 (46.4%)
56 (44.4%)
0.761
Carbapenems (467 vs. 126)c
550 (92.6%)
435 (92.9%)
115 (91.3%)
0.673
Tigecycline (391 vs. 106)c
165 (27.8%)
135 (28.8%)
30 (23.8%)
0.475
Colistin (253 vs. 57)c
9 (1.5%)
9 (1.9%)
0 (0%)
0.083
Treatment after the onset of BSIs
Appropriate empiric antibiotic treatment
169 (28.5%)
120 (25.6%)
49 (38.9%)
0.003
aBiliary tract, heart surgery, urinary tract, and intraabdominal. bAB: Acinetobacter baumannii; not all agents listed tested in all isolates. cThe numbers in parentheses represent the total numbers of AB isolates that were subjected to susceptibility testing.
